3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
42
Neoplasms
14
Carcinoma, Hepatocellular
9
Gastrointestinal Stromal Tumors
7
Liver Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Glioblastoma
2
Esophageal Squamous Cell Carcinoma
2
Astrocytoma
2
Advanced Cancer
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Renal Insufficiency
1
Rectal Neoplasms
1
Physician Education
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Melanoma
1
Interventions
pembrolizumab
3
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
regorafenib
1
binimetinib
1
Nivolumab
1
Irinotecan
1
Fulvestrant
1
E7046
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Spinocerebellar Degenerations
×
regorafenib
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled